RPS5

Small ribosomal subunit protein uS7 · P46782 · RPS5 on Sugi Atlas →

3,660 patent compounds predicted against RPS5, 1,918 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPS5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
Natural History and Genetic Studies of Usher Syndrome	nan	COMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPS5 binder may also engage these)

Protein	Name	Similarity
G1TFM5	—	1.000	G1TFM5 →
Q5E988	—	1.000	Q5E988 →
P24050	—	1.000	P24050 →
Q9P3T6	—	1.000	Q9P3T6 →
P97461	—	1.000	P97461 →
P51427	—	1.000	P51427 →
O15587	—	1.000	O15587 →
Q08364	—	1.000	Q08364 →
O14277	—	1.000	O14277 →
Q24186	—	1.000	Q24186 →
P49041	—	1.000	P49041 →
Q7RVI1	—	1.000	Q7RVI1 →
P29159	—	0.999	P29159 →
Q9ZUT9	—	0.998	Q9ZUT9 →
A2STX0	—	0.997	A2STX0 →
Q2FS70	—	0.997	Q2FS70 →
Q54MA6	—	0.996	Q54MA6 →
A8MBL5	—	0.996	A8MBL5 →
Q9HLY1	—	0.996	Q9HLY1 →
P26783	—	0.995	P26783 →
Q2NEK9	—	0.995	Q2NEK9 →
Q9VFE4	—	0.995	Q9VFE4 →
Q6L0R3	—	0.995	Q6L0R3 →
A0RUR1	—	0.995	A0RUR1 →
O65731	—	0.994	O65731 →
Q74MR5	—	0.994	Q74MR5 →
A5CF22	—	0.994	A5CF22 →
A6UV45	—	0.994	A6UV45 →
A9A9U5	—	0.993	A9A9U5 →
Q8SS72	—	0.993	Q8SS72 →